Peptide LexiconAll compounds

Rusfertide (Mimrylo): The Hepcidin-Copy Peptide Approved in 2026 for Polycythemia Vera

Rusfertide is a synthetic ring-shaped peptide that copies the iron hormone hepcidin. The FDA approved it as Mimrylo on 28 August 2026 for erythrocytosis in adults with polycythemia vera. This entry covers its structure, how starving red-cell production of iron works, the REVIVE and VERIFY trials and the label's platelet warning.

Approved drug (US, 2026)Prescription onlyWeekly injection

Caroline S · Published 2026-11-17

Length

17 amino acids in a disulfide ring, plus an isovaleryl cap and a palmitoyl fatty-acid chain — C114H181N27O28S2, molecular weight 2,442.0 (free base, Mimrylo label)

Sequence

isovaleryl-DTHFPCIK(palmitoyl-γ-Glu)FEPRSKGCK-NH2, disulfide between positions 6 and 16 (Mimrylo label, section 11)

Origin

Synthetic hepcidin mimetic; developed by Protagonist Therapeutics, marketed in the US by Takeda

Last reviewed

2026-11-17

What is it good for?

Rusfertide is approved in the United States for erythrocytosis — too many red blood cells — in adults with polycythemia vera. In its phase 3 trial, 77% of patients on rusfertide and 33% on placebo no longer qualified for blood removal (phlebotomy) between weeks 20 and 32. It does not treat the bone-marrow disease itself; it limits the iron that red-cell production needs.

Illustration: A ring-shaped molecular model and a small clear glass vial on a white surface with copper reflection.
Illustration

What it is

Rusfertide is a synthetic peptide built to do the job of hepcidin, the liver hormone that rations iron. The FDA approved it on 28 August 2026 as Mimrylo (Takeda, NDA 220605), under priority review as a new molecular entity, for erythrocytosis in adults with polycythemia vera (Drugs@FDA, read 2026-11-17). It reached that point under the code PTG-300 from its developer, Protagonist Therapeutics, whose staff co-authored the trial papers.

The label's chemical name describes the molecule exactly (Mimrylo label, section 11, revision 2026-11-07):

Property Value Source
Chain 17 amino acids, DTHFPCIKFEPRSKGCK, C-terminal amide Mimrylo label
Ring Disulfide bond between Cys6 and Cys16 Mimrylo label
Added groups Isovaleryl cap at the start; palmitoyl-γ-Glu on Lys8 Mimrylo label
Formula (free base) C114H181N27O28S2 Mimrylo label
Molecular weight 2,442.0 Mimrylo label
Salt Acetate Mimrylo label

How much of hepcidin is in it. Human hepcidin-25 is DTHFPICIFCCGCCHRSKCGMCCKT (UniProt P81172). Lined up against the label sequence, the first five amino acids, DTHFP, are identical; after that the two diverge (our comparison). Rusfertide has one disulfide bond where hepcidin has four, and carries a fatty-acid chain hepcidin does not. The label gives it as a once-weekly injection.

How it works

Hepcidin controls iron by making cells destroy ferroportin, the channel iron leaves them through — the full mechanism is in the library's hepcidin entry. Rusfertide copies that effect. In polycythemia vera the bone marrow over-produces red cells — production that in health is set by the kidney hormone erythropoietin; restricting iron slows production and lowers haematocrit, the share of blood made of red cells. The standard treatment is phlebotomy, regular blood removal; in both trials the measure of success was how far rusfertide reduced the need for it.

It does not act on the mutated marrow cells that cause the disease. Patients in both trials stayed on their existing treatment, including phlebotomy and, in many, cytoreductive drugs.

What the trials showed

Trial People Design Result Source
REVIVE, phase 2 70 enrolled; 59 randomised in part 2 28-week dose-finding, then 12-week randomised withdrawal Phlebotomies estimated 8.7 a year before vs 0.6 during part 1; response 60% vs 17% placebo in part 2 Kremyanskaya 2024, NEJM, PMID 38381675
VERIFY, phase 3 293 (147 rusfertide, 146 placebo) 32 weeks, double-blind, on top of standard care Clinical response 77% vs 33%; phlebotomies 0.5 vs 1.8; haematocrit below 45% in 63% vs 14% Kuykendall 2026, J Clin Oncol, PMID 42868322
Haemochromatosis, phase 2 16 Open label, no control arm, no prespecified primary endpoint 15 of 16 phlebotomy-free over 24 weeks (2.31 phlebotomies in the 24 weeks before) Lancet Gastroenterol Hepatol 2023, PMID 37863080

The VERIFY label population was 73% male, mean age 57, and 89% White. Patient-reported fatigue and symptom scores improved more on rusfertide than on placebo (P = .025 and .024). No deaths were reported in the trial.

What the haemochromatosis study can and cannot show: with no control group and no primary endpoint, it is a signal, not proof, and haemochromatosis is not on the label.

Safety on the label

  • New or worsening thrombocytosis (high platelets): within four weeks platelets rose by an average of 31%; 36% of patients went above 600 × 10⁹/L and 6% above 1,000 × 10⁹/L. Counts generally levelled off by week 8; 1% stopped the drug for it. The label calls for blood counts every 2 to 4 weeks after starting and after dose changes.
  • Injection-site reactions in 56% and anaemia in 16% were the most common adverse reactions.
  • Embryo-fetal toxicity: based on animal data the label warns it can cause fetal harm; there are no human pregnancy data.

Where it stands

Rusfertide is a prescription medicine with one approved use. It is not a research peptide, and the label is the only source of dosing figures here, reported as written. Decisions about polycythemia vera treatment belong to a haematologist. ClinicalTrials.gov lists six rusfertide studies (2026-11-17), including a long-term safety extension and phase 2 studies in China and Japan.

Sources opened 2026-11-17: Mimrylo prescribing information (openFDA, revision 2026-11-07); Drugs@FDA NDA 220605; UniProt P81172; Kuykendall et al. 2026 (PMID 42868322); Kremyanskaya et al. 2024 (PMID 38381675); haemochromatosis phase 2, 2023 (PMID 37863080); PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Controls haematocrit in polycythemia vera

VERIFY phase 3, Kuykendall et al. 2026, J Clin Oncol (PMID 42868322): 293 patients, 32 weeks; clinical response 77% vs 33%; haematocrit kept below 45% in 63% vs 14%

Cuts the need for phlebotomy

REVIVE phase 2, Kremyanskaya et al. 2024, N Engl J Med (PMID 38381675): 70 enrolled; estimated phlebotomies 8.7 a year before vs 0.6 during treatment; randomised withdrawal response 60% vs 17%

Reduces iron overload in haemochromatosis

Open-label phase 2, Lancet Gastroenterol Hepatol 2023 (PMID 37863080): 16 patients, no control arm, no prespecified primary endpoint; 15 of 16 phlebotomy-free over 24 weeks

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Mimrylo, NDA 220605, Takeda; approved 2026-08-28, priority review, new molecular entity (Drugs@FDA). Indication: erythrocytosis in adults with polycythemia vera.

Form on the label

Powder for subcutaneous injection in five vial strengths, 9.5 mg to 54 mg; the label gives a weekly range of 9.5 mg to 108 mg. Reported as the label states it, not as guidance.

Published record

PubMed: 22 records naming rusfertide, 5 tagged as randomised trials. ClinicalTrials.gov: 6 studies, two of them phase 3 (2026-11-17).

Frequently asked questions

What is rusfertide?

A synthetic peptide that copies hepcidin, the hormone that controls how much iron enters the blood. It is sold in the United States as Mimrylo, a weekly injection approved in August 2026 for adults with polycythemia vera who make too many red blood cells.

How does rusfertide work?

Like hepcidin, it closes the door iron uses to leave cells and enter the blood. Red-cell production needs iron, so restricting the supply slows it, and haematocrit falls without removing blood.

What is the brand name of rusfertide?

Mimrylo, marketed in the United States by Takeda under NDA 220605. During development it was called PTG-300, the code used by its developer, Protagonist Therapeutics.

How well did rusfertide work in trials?

In the 293-patient VERIFY trial, 77% on rusfertide and 33% on placebo stopped qualifying for phlebotomy between weeks 20 and 32, and 63% against 14% kept haematocrit below 45%.

What are the side effects of rusfertide?

On the label, injection-site reactions (56%) and anaemia (16%) were the most common. The label also warns of new or worsening high platelet counts and of possible harm to a fetus based on animal data.

Is rusfertide the same as hepcidin?

No. Hepcidin is 25 amino acids with four disulfide bonds. Rusfertide is a 17-amino-acid ring with one disulfide bond and a fatty-acid chain that keeps it in the body longer; only its first five amino acids match hepcidin's.